New COVID Vaccine Approved – FDA Update
- The Food and Drug Management (FDA) has approved Moderna's new COVID vaccine, mNEXSPIKE, for adults aged 65 and older, as well as individuals between 12 and 64 who...
- The CDC defines underlying risk factors as conditions such as cancer, asthma, and HIV.
- Moderna CEO Stéphane Bancel stated the new COVID vaccine is an "critically important new tool to help protect peopel at high risk of severe disease." Bancel noted that...
The FDA has approved Moderna’s mNEXSPIKE COVID vaccine, specifically for adults 65+ and at-risk individuals, marking a notable update in the fight against the virus. Clinical trials revealed mNEXSPIKE to be more effective than its predecessor, offering enhanced protection. This progress arrives amid shifting CDC recommendations, sparking concerns about access and coverage for the primary_keyword. Concerns that a secondary_keyword like vaccine hesitancy may arise are on the horizon. Moderna’s CEO highlights the vaccine’s critical role in safeguarding vulnerable populations. However, changes in vaccine guidelines, like those impacting healthy children, could pose challenges. News Directory 3 will continue to monitor the situation. Will insurance coverage and public perception adapt? Discover what’s next.
FDA Approves Moderna COVID Vaccine for Adults 65+ and High-Risk Groups
Updated June 01, 2025
The Food and Drug Management (FDA) has approved Moderna’s new COVID vaccine, mNEXSPIKE, for adults aged 65 and older, as well as individuals between 12 and 64 who have underlying risk factors. Moderna announced the approval in a press release Saturday.
The CDC defines underlying risk factors as conditions such as cancer, asthma, and HIV. A clinical trial involving over 11,000 participants demonstrated that the mNEXSPIKE vaccine had a higher efficacy rate then Moderna’s previous COVID-19 vaccine.
Moderna CEO Stéphane Bancel stated the new COVID vaccine is an ”critically important new tool to help protect peopel at high risk of severe disease.” Bancel noted that COVID “remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone.”
The FDA’s approval follows recent announcements regarding changes to COVID vaccine recommendations. Health and Human Services (HHS) Secretary Robert F.Kennedy Jr.stated in a video posted on X that the CDC would drop its advice for COVID vaccines for healthy children and pregnant women. This decision was reportedly made outside the agency’s formal expert review process. Previously, vaccination was advised for everyone 6 months and older.
The CDC has as clarified its guidance, stating that healthy children can still receive the vaccine through “shared clinical decision-making” between parents and doctors. The American Academy of Family Physicians and the American Academy of Pediatrics continue to recommend COVID vaccination for children.
experts have voiced concerns that these changes in recommendations could impact vaccine access. Richard Hughes, a former Moderna executive and George Washington University health care law lecturer, told NPR to “expect variability in coverage, prior authorization and out-of-pocket [costs], all of which will discourage uptake.”
What’s next
The impact of the FDA’s approval of Moderna’s mNEXSPIKE COVID vaccine may be tempered by evolving recommendations and potential challenges in insurance coverage and access. Continued monitoring of vaccination rates and disease trends will be crucial.